Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer

Summary

The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer receiving primary radiation therapy (RT) results in an improvement of disease-free survival (DFS) evaluated by the treating physician, in comparison to the combination of radiation and androgen deprivation therapy without the addition of apalutamide.

Timeline

Start

2020-03-10

Primary completion

2026-06-15

Completion

2026-06-15

Drugs

Indications